The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

Journal of Experimental Medicine

Volumn 199, Issue 12, 2004, Pages 1659-1669

  Uchida, Junji ^a   Hamaguchi, Yasuhito ^a   Oliver, Julie A ^a   Ravetch, Jeffrey V ^b   Poe, Jonathan C ^a   Haas, Karen M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Autoimmune diseases; Lymphoma; Mouse model; Rituximab; Therapy

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD20; B-LYMPHOCYTES; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; PHAGOCYTES; RECEPTORS, IGG; SPLEEN;

EID: 3042592452     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20040119     Document Type: Article

References (76)

1. Tedder, T.F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today. 15: 450-454.
2. Press, O.W., J.P. Leonard, B. Coiffier, R. Levy, and J. Timmerman. 2001. Immunotherapy of non-Hodgkin's lymphomas. Hematology. (Am. Soc. Hematol. Educ. Program). 2001:221-240.
3. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:459-465.
4. Weiner, L.M. 1999. Monoclonal antibody therapy of cancer. Semin. Oncol. 26:43-51.
5. Onrust, S.V., H.M. Lamb, and J.A. Balfour. 1999. Rituximab. Drugs. 58:79-88.
6. McLaughlin, P., C.A. White, A.J. Grillo-Lopez, and D.G. Maloney. 1998. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology. 12:1763-1769.
7. Silverman, G.J., and S. Weisman. 2002. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48:1484-1492.
8. Edwards, J.C.W., and G. Cambridge. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol. 40:1-7.
9. Smith, M.R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 22: 7359-7368.
10. Reff, M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, and N. Hanna. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:435-445.
11. Maloney, D.G., A.J. Grillo-López, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:2188-2195.
12. Maloney, D.G., L.A. Grillo, D.J. Bodkin, C.A. White, T.M. Liles, I. Royston, C. Varns, J. Rosenberg, and R. Levy. 1997. IDEC-C2B8: results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:3266-3274.
13. Shan, D., J.A. Ledbetter, and O.W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 91:1644-1652.
14. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytec leukemia: further regulation by CD55 and CD59. Blood. 98:3383-3389.
15. Cragg, M.S., M.S. M., H.T. Chan, B.P. Morgan, A.V. Falatov, P.W. Johnson, R.R. French, and M.J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 101:1045-1052.
16. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of Rituximab in vivo. J. Immunol. 171:1581-1587.
17. Bellosillo, B., N. Villamor, A. López-Guillermo, S. Marcé, J. Esteve, E. Campo, D. Colomer, and E. Montserrat. 2001. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 98:2771-2777.
18. van der Kolk, L.E., A.J. Grillo-López, J.W. Baars, C.E. Hack, and M.H.J. van Oers. 2001. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115:807-811.
19. + cells by rituximab. Blood. 101:1071-1079.
20. Treon, S.P., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K.C. Anderson. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24:263-271.
21. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazzari, G.M. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 95:3900-3908.
22. Di Gaetano, N., Y. Xiao, E. Erba, R. Bassan, A. Rambaldi, J. Golay, and M. Introna. 2001. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activitiy of either drug alone. Br. J. Haematol. 114:800-809.
23. Weiner, G.J. 2003. Rituximab: complementary mechanisms of action. Blood. 101:788.
24. Weng, W.-K., and R. Levy. 2001. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 98:1352-1357.
25. Anderson, D.R., A. Grillo-López, C. Varns, K.S. Chambers, and N. Hanna. 1997. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25:705-708.
26. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-446.
27. Demidem, A., T. Lam, S. Alas, K. Hariharan, H. Hanna, and B. Bonavida. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177-186.
28. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J.A. Oliver, K. Bowen, D.A. Steeber, K.M. Haas, J.C. Poe, et al. 2004. Mouse CD20 expression and function. Int. Immunol. 16:119-129.
29. Sato, S., N. Ono, D.A. Steeber, D.S. Pisetsky, and T.F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:4371-4378.
30. Zhou, L.-J., H.M. Smith, T.J. Waldschmidt, R. Schwarting, J. Daley, and T.F. Tedder. 1994. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol. Cell. Biol. 14: 3884-3894.
31. Bruhns, P., A. Samuelsson, J.W. Pollard, and J. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-581.
32. Botto, M., M.C. Dell'Agnola, A.E. Bygrave, E.M. Thompson, H.T. Cook, F. Petry, M. Loos, P.P. Pandolfi, and M.J. Walport. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56-59.
33. Zhang, W., C.L. Sommers, D.N. Burshtyn, C.C. Stebbins, J.B. DeJamette, R.P. Trible, A. Grinberg, H.C. Tsay, H.M. Jacobs, C.M. Kessler, et al. 1999. Essential role of LAT in T cell development. Immunity. 10:323-332.
34. Wessels, M.R., P. Butko, M. Ma, H.B. Warren, A. Lage, and M.C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA. 92:11490-11494.
35. Van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods. 174:83-93.
36. Gazzano-Santoro, H., P. Ralph, T.C. Ryskamp, A.B. Chen, and V.R. Mukku. 1997. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J. Immunol. Methods. 202:163-171.
37. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J.V. Ravetch. 1994. FcR γ chain depletion results in pleiotrophic effector cell defects. Cell. 76:519-529.
38. Ravetch, J.V., and R.A. Clynes. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16: 421-432.
39. Fossati-Jimack, L., A. Ioan-Facsinay, L. Reininger, Y. Chicheportiche, N. Watanabe, T. Saito, F.M.A. Hofhuis, J.E. Gessner, C. Schiller, R.E. Schmidt, et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191:1293-1302.
40. Hazenbos, W.L.W., J.E. Gessner, F.M.A. Hofhuis, H. Kuipers, D. Meyer, I.A.F.M. Heijnen, R.E. Schmidt, M. Sandor, P.J.A. Capel, M. Daëron, et al. 1996. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity. 5:181-188.
41. Cecchini, M.G., M.G. Dominguez, S. Mocci, A. Wetterwald, R. Felix, H. Fleisch, O. Chisholm, W. Hofstetter, J.W. Pollard, and E.R. Stanley. 1994. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development. 120:1357-1372.
42. Kagi, D., B. Ledermann, K. Burki, P. Selleer, B. Odermatt, K.J. Olsen, E.R. Podack, R.M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:31-37.
43. Dyall, R., L.V. Vasovic, R.A. Clynes, and J. Nikolic-Zugic. 1999. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29:30-37.
44. Herlyn, D., and H. Koprowski. 1982. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA. 79:4761-4765.
45. Isaacs, J.D., M.R. Clark, J. Greenwood, and H. Waldmann. 1992. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148:3062-3071.
46. H3 domains on in vivo effector function. J. Immunol. 161:3862-3869.
47. Ansell, S.M., T.E. Witzig, P.J. Kurtin, J.A. Sloan, D.F. Jelinek, K.G. Howell, S.N. Markovic, T.M. Habermann, G.G. Klee, P.J. Atherton, et al. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 99:67-74.
48. Kaminski, M.S., K. Kitamura, D.G. Maloney, M.J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136:1123-1130.
49. Denkers, E.Y., C.C. Badger, J.A. Ledbetter, and I.D. Bernstein. 1985. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 135:2183-2186.
50. Liu, A.Y., R.R. Robinson, E.D. Murray, Jr., J.A. Ledbetter, I. Hellströom, and K.E. Hellström. 1987. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139:3521-3526.
51. Azeredo da Silveira, S., S. Kikuchi, L. Fossati-Jimack, T. Moll, T. Saito, J.S. Verbeek, M. Botto, M.J. Walport, M. Carroll, and S. Izui. 2002. Complement activation selectively potentiates the pathogenecity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J. Exp. Med. 195:665-672.
52. Ioan-Facsinay, A., S.J. de Kimpe, S.M.M. Hellwig, P.L. van Lent, F.M.A. Hofhuis, H.H. van Ojik, C. Sedlik, S.A. da Silveira, J. Gerber, Y.F. de Jong, et al. 2002. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 16:391-402.
53. Fossati-Jimack, L., L. Reininger, Y. Chicheportiche, R. Clynes, J.V. Ravetch, T. Honjo, and S. Izui. 1999. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J. Exp. Med. 190:1689-1696.
54. Gavin, A.L., N. Barnes, H.M. Dijstelbloem, and P.M. Hogarth. 1998. Cutting edge: identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J. Immunol. 160:20-23.
55. Dijstelbloem, H.M., J.G.J. van de Winkel, and C.G.M. Kallenberg. 2001. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22:510-516.
56. Samuelsson, A., T.L. Towers, and J.V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:484-486.
57. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 99:754-758.
58. Anolik, J.H., D. Campbell, R.E. Felgar, F. Young, I. Sanz, J. Rosenblatt, and R.J. Looney. 2003. The relationship of FcgRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455-459.
59. Weng, W.-K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximan in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
60. Neuberger, M.S., and K. Rajewsky. 1981. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 11:1012-1016.
61. Klaus, G.G., M.B. Pepys, K. Kitajima, and B.A. Askonas. 1979. Activation of mouse complement by different classes of mouse antibody. Immunology. 38:687-695.
62. Meyer, D., C. Schiller, J. Westermann, S. Izui, W.L.W. Hazenbos, J.S. Verbeek, R.E. Schmidt, and J.E. Gessner. 1998. FcgRIII (CD16)-deficient mice show IgG isotype dependent protection to experimental autoimmune hemolytic anemia. Blood. 92:3997-4002.
63. Sylvestre, D.L., R. Clynes, M. Ma, H. Warren, M.C. Caroll, and J.V. Ravetch. 1996. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184:2385-2392.
64. Cragg, M.S., and M.J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 103:2738-2743.
65. Nadler, L.M., T. Takvorian, L. Botnick, R.C. Bast, R. Finberg, S. Hellman, G.P. Canellos, and S.F. Schlossman. 1984. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 2:427-431.
66. Reddy, M.P., C.A.S. Kinney, M.A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P.R. Dal Monte, M.L. Doyle, M.R. Brigham-Burke, D. Anderson, et al. 2000. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164:1925-1933.
67. Mathas, S., A. Rickers, K. Bommert, B. Dorken, and M.Y. Mapara. 2000. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60:7170-7176.
68. Shan, D., J.A. Ledbetter, and O.W. Press. 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48:673-683.
69. Winkler, U., M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert. 1999. Cytokine-release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 94:2217-2224.
70. Farag, S.S., I.W. Flinn, R. Modali, T.A. Lehman, D. Young, and J.C. Byrd. 2004. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 103:1472-1474.
71. Stockmeyer, B., M. Schiller, R. Repp, H.M. Lorenz, J.R. Kalden, M. Gramatzki, and T. Valerius. 2002. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10-a humanized human leukocyte antigen DR antibody. Brit. J. Haematol. 118:959-967.
72. van der Kolk, L.E., M. de Haas, A.J. Grillo-Lopez, J.W. Baars, and M.H. van Oers. 2002. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia. 16:693-699.
73. Stockmeyer, B., D. Elsasser, M. Dechant, R. Repp, M. Gramatzki, M.J. Glennie, J.G. van de Winkel, and T. Valerius. 2001. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J. Immunol. Methods. 248:103-111.
74. Elasser, D., T. Valerius, R. Repp, G.J. Weiner, Y. Deo, J.R. Kalden, J.G. van de Winkel, G.T. Stevenson, M.J. Glennie, and M. Gramatzki. 1996. HLA class 11 as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood. 87:3803-3812.
75. Coiffier, B., C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. Feuring-Buske, J.A. Radford, et al. 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 92:1927-1932.
76. McLaughlin, P., L.A. Grillo, B.K. Link, R. Levy, M.S. Czuczman, M.E. Williams, M.R. Heyman, B.I. Bence, C.A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-2833.